|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species显示文摘 | Chen-chun ZHONG Feng CHEN Jun-ling YANG Wei-wei JIA Li LI Chen CHENG Fei-fei DU Su-ping ZHANG Chengying XIE Na-ting ZHANG Olajide E OLALEYE Feng-qing WANG Fang XU Li-guang LOU Dong-ying CHEN Wei NIU Chuan LI | 2018 | Acta Pharmacologica Sinica2018，39，6： | 24 |
| 2 | Pharmacokinetics and disposition of monoterpene glycosides derived from Paeonia lactiflora roots (Chishao) after intravenous dosing of antiseptic XueBiJing injection in human subjects and rats显示文摘瞄准:从 Paeonia lactiflora 根(Chishao ) 导出的 Monoterpene glycosides 被相信为防腐草药的注射 XueBiJing pharmacologically 重要。这研究被设计描绘 monoterpene glycosides.Methods 的 pharmacokinetics 和布置:到 Chishao monoterpene glycosides 的全身的暴露在收到静脉内的注入和 XueBiJing 注射的多重注入的人的题目被估计,由对主要传播混合物的 pharmacokinetics 的评价列在后面。支持的老鼠研究也被执行。膜渗透和血浆蛋白质绑定在 vitro.Results 被估计:18 monoterpene glycosides 的一个总数在 XueBiJing 注射被检测(内容层次, 0.001-2.47 mmol/L ) ,并且 paeoniflorin 说明了检测的 monoterpene glycosides 的 85.5% 全部的剂量。在人的题目,未改变的 paeoniflorin 与 1.2-1.3 h 的消除一半生活展出了全身的暴露的可观的层次;没有重要代谢物被检测。Oxypaeoniflorin 和 albiflorin 展出了低暴露层次,并且留下的次要的 monoterpene glycosides 可以忽略或未被发现。Glomerular-filtration-based 肾的排泄是 paeoniflorin 的主要消除小径,它血浆蛋白质糟糕一定。在老鼠,当剂量被增加, paeoniflorin 的全身的暴露水平按比例增加了。老鼠肺,心,和 paeoniflorin 的肝暴露层次比血浆水平低,与肾水平的例外,它是比血浆水平大的 4.3 褶层;大脑穿入被差的膜 permeability.Conclusion 限制:由于它的重要全身的暴露和适当 pharmacokinetic 侧面,以及以前报导了防腐性质, paeoniflorin 是治疗学的重要性的有希望的 XueBiJing 成分。 | Chen CHENG Jia-zhen LIN Li LI Jun-ling YANG Wei-wei JIA Yu-hong HUANG Fei-fei DU Feng-qing WANG Mei-juan LI Yan-fen LI Fang XU Na-ting ZHANG Olajide E. OLALEYE Yan SUN Jian LI Chang-hai SUN Gui-ping ZHANG Chuan LI | 2016 | Acta Pharmacologica Sinica2016，37，4： | 15 |
| 3 | Intravenous formulation of Panax notoginseng root extract:human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions显示文摘XueShuanTong,a lyophilized extract of Panax notoginseng roots(Sanqi)for intravenous administration,is extensively used as add-on therapy in the treatment of ischemic heart and cerebrovascular diseases and comprises therapeutically active ginsenosides.Potential for XueShuanTong-drug interactions was determined;the investigation focused on cytochrome P450(CYP)3A induction and organic anion-transporting polypeptide(OATP)1 B inhibition.Ginsenosides considerably bioavailable for drug interactions were identifed by dosing XueShuanTong in human subjects and their interaction-related pharmacokinetics were determined.The CYP3A induction potential was determined by repeatedly dosing XueShuanTong for 15 days in human subjects and by treating cryopreserved human hepatocytes with circulating ginsenosides;midazolam served as a probe substrate.Joint inhibition of OATP1B by XueShuanTong ginsenosides was assessed in vitro,and the data were processed using the Chou-Talalay method,Samples were analyzed by liquid chromatography/mass spectrometry.Ginsenosides Rb1,Rd,and Rg1 and notoginsenoside R were the major circulating XueShuanTong compounds;their interaction-related pharmacokinetics comprised compound dose-dependent levels of systemic exposure and,for ginsenosides Rb,and Rd,long terminal hal-lives(32-57 and 58-307 h,respectively)and low unbound fractions in plasma(0.8%-2.9%and 0.4%-3.0%,respectively).Dosing XueShuanTong did not induce CYP3A.Based on the pharmacokinetics and inhibitory potency of the ginsenosides,XueShuanTong was predicted to have high potential for OATP1B3-mediated drug interactions(attributed chiefly to ginsenoside Rb,)suggesting the need for further model-based determination of the interaction potential for XueShuanTong and,if necessary,a clinical drug interaction study.Increased awareness of ginsenosides'pharmacokinetics and XueShuanTong-drug interaction potential will help ensure the safe use of XueShuanTong and coadministered synthetic drugs. | Salisa Pintusophon Wei Niu Xiao-na Duan Olajide E Olaleye Yu-hong Huang Feng-qing Wang Yan-fen Li Jun-ling Yang Chuan Li | 2019 | Acta Pharmacologica Sinica2019，40，10： | 13 |
| 4 | 红花的化学成分及DPPH自由基清除活性研究显示文摘从红花中分离得到14个化合物,通过波谱数据和理化性质分别鉴定为:异光黄素(1)、(2S)-4',5,6,7-四羟基二氢黄酮-6-O-β-D-葡萄糖苷(2)、新红花苷(3)、山柰酚(4)、山柰酚-3-O-β-D-葡萄糖苷(5)、山柰酚-3-O-β-芸香糖苷(6)、6-羟基山柰酚(7)、6-羟基山柰酚-3-O-β-D-葡萄糖苷(8)、槲皮素(9)、对羟基苯甲酸(10)、对羟基桂皮酸(11)、尿嘧啶(12)、腺嘌呤(13)、β-谷甾醇(14),其中化合物1首次从红花属植物中分离得到。采用TLC-DPPH生物自显影法筛选单体化合物及红花醇提物各萃取部位的自由基清除活性,结果表明乙酸乙酯萃取物及化合物4、9、11具有明显的DPPH自由基清除活性。 | Olaleye Olajide 李珊珊 刘海涛 柴欣 王跃飞 高秀梅 | 2014 | 天然产物研究与开发2014，26，1： | 10 |
| 5 | LC/MS/MS determination and pharmacokinetic studies of six compounds in rat plasma following oral administration of the single and combined extracts of Eucommia ulmoides and Dipsacus asperoides显示文摘AIM: To establish and apply a new LC/MS/MS method for the simultaneous, quantitative determination of six ingredients, aucubin(AU), geniposide(GP), geniposidic acid(GPA), pinoresinol diglucoside(PDG), secologanin(SLG), and loganin(LG) in single and combined extracts of Eucommia ulmoides and Dipsacus asperoides. METHOD: Using the LC/MS/MS-ESI--MRM mode to detect the six compounds, chromatographic separation was achieved on an Agilent Eclipse plus C18 column, and the mobile phase consisted of solvent A(CH3CN) and solvent B(H2O containing 0.01% CH3 COOH V/V). RESULTS: This method was successfully applied to quantify the six compounds in rat plasma after oral administration, and showed good precision, accuracy, reproducibility, and linear regression(r2 >0.99). CONCLUSION: The results showed that following the use of the two medicinal plants, for AU and GP, the values of tmax markedly increased, and the values of cmax markedly decreased. It was found that the compatibility of the medicinal plants might affect their pharmacokinetic properties of their constituents. | HUANG Yu-Xing LIU Er-Wei WANG Lei HUO Yan WANG Qiang OLALEYE Olajide WANG Tao GAO Xiu-Mei | 2014 | Chinese Journal of Natural Medicines2014，12，6： | 7 |
| 6 | Multiple circulating saponins from intravenous ShenMai inhibit OATPIBs in vitro: potential joint precipitants of drug interactions显示文摘ShenMai, an intravenous Injection prepared from steamed Hanax ginseng roots (Hongshen) and Ophiopogon japonicus roots (Maidong), is used as an add-on therapy for coronary artery disease and cancer;saponins are its bioactive constituents. Since many saponins inhibit human organic anion-transporting polypeptides (OATP11B, this investigation determined the inhibition potencies of circulating ShenMai saponins on the transporters and the joint potential of these compounds for ShenMai drug interaction. Circulating saponins and their pharmacokinetics were charaaerized in rats receiving a 30-min infusion of ShenMai at 1OmL/kg. Inhibition of human OATP1B1/1B3 and rat Oatplb2 by the individual saponins was investigated in vitro;the compounds, joint inhibition was also assessed in vitro and the data was processed using the Chou-Talalay method. Plasma protein binding was assessed by equilibrium dialysis. Altogether, 49 saponins in ShenMai were characterized and graded into: 10-1OOμmol/day (compound doses from ShenMai;7 compounds), 1-10 μmol/day (17 compounds), and <1μmol/day (25 compounds, including Maidong ophiopogonins). After dosing, circulating saponins were protopanaxadiol-type ginbenosides Rbi, Rb2r Rc, Rd, Rg2, and Ra3, protopanaxatriol-type ginsenosides Rg1, Re, Rg2, and Rf, and ginsenoside Ro. The protopanaxadiol-type ginsenosides exhibited maximum plasma concentrations of 2.1-46.6 μmol/L, plasma unbound fractions of 0.4-1.0% and terminal half-lives of 15.6-28.5 h (ginsenoside Rg3f 1.9 h), while the other ginsenosides exhibited 0.1-77 μmol/L, 20.8-99.2%, and 0.2-0.5 h, respectively. The protopanaxadiol-type ginsenosides, ginsenosides without any sugar attachment at C-20 (except ginsenoside Rf), and ginsenoside Ro inhibited OATP1B3 more potently (IC50, 0.2-3.5 (μmol/L) than the other ginsenosides (≥22.6 μmol/L). Inhibition of OATP1B1 by ginsenosides was less potent than OATP1B3 inhibition. Ginsenosides Rb1;Rb2, Rc, Rd, Ro, Ra1, Re, and Rg2 likely contribute the major part of OATP1B3-mediated ShenMai-drug interaction potential, in an additive and time-related manner. | Olajide E. Olaleye Wei Niu Fei-fei Du Feng-qing Wang Fang Xu Salisa Pintusophon Jun-lan Lu Jun-ling Yang Chuan Li | 2019 | Acta Pharmacologica Sinica2019，40，6： | 7 |
| 7 | Composition analysis of Compound Shenhua Tablet,a seven-herb Chinese medicine for IgA nephropathy:evaluation of analyte-capacity of the assays显示文摘Compound Shenhua Tablet,a medicine comprising seven herbs,is employed in treating IgA nephropathy.This study aimed to meticulously analyze its chemical composition.Based on a list of candidate compounds,identified through extensive literature review pertinent to the tablet’s herbal components,the composition analysis entailed the systematic identification,characterization,and quantification of the constituents.The analyte-capacity of LC/ESI-MS-based and GC/EI-MS-based assays was evaluated.The identified and characterized constituents were quantified to determine their content levels and were ranked based on the constituents’daily doses.A total of 283 constituents,classified into 12 distinct categories,were identified and characterized in the Compound Shenhua Tablet.These constituents exhibited content levels of 1−10982μg·g^(−1),with daily doses of 0.01−395μmol·d^(−1).The predominant constituents,with daily doses of≥10μmol·d^(−1),include nine organic acids(citric acid,quinic acid,chlorogenic acid,cryptochlorogenic acid,gallic acid,neochlorogenic acid,isochlorogenic acid C,isochlorogenic acid B,and linoleic acid),five iridoids(specnuezhenide,nuezhenoside G13,nuezhenidic acid,secoxyloganin,and secologanoside),two monoterpene glycosides(paeoniflorin and albiflorin),a sesquiterpenoid(curzerenone),a triterpenoid(oleanolic acid),and a phenylethanoid(salidroside).Additionally,there were 83,126,and 55 constituents detected in the medicine with daily doses of 1–10,0.1–1,and 0.01–0.1μmol·d^(−1),respectively.The combination of the LC/ESI-MS-based and GC/EI-MS-based assays demonstrated a complementary relationship in their analyte-capacity for detecting the constituents present in the medicine.This comprehensive composition analysis establishes a solid foundation for further pharmacological research on Compound Shenhua Tablet and facilitates the quality evaluation of this complex herbal medicine. | ZHANG Haiyan WANG Qiuyue WANG Jianan ZHANG Sichao JIA Weiwei HE Ning XIA Xiaoyan WANG Ting LAI Liyu LI Jiaying DU Jing OLALEYE Olajide E CHEN Xiangmei YANG Junling LI Chuan | 2024 | Chinese Journal of Natural Medicines2024，22，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员